Cambium BioASX:CMB +2.38%35 Net Current Asset Value is A$0.01 as of Dec. 2025, which is 100% below its 10-year median of 10.30. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 946 Biotechnology companies, Cambium Bio ranks worse than 93.45% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Cambium Bio's net current asset value per share for the quarter that ended in Dec. 2025 was A$0.01.
The historical rank and industry rank for Cambium Bio's Net Current Asset Value or its related term are showing as below:
ASX:CMB'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.34 Med: 10.3 Max: 47
Current: 43
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of Cambium Bio was 47.00. The lowest was 3.34. And the median was 10.30.
ASX:CMB's Price-to-Net-Current-Asset-Value is ranked worse than 93.45% of 946
companies
in the Biotechnology industry
Industry Median: 4.86
vs ASX:CMB: 43.00
Cambium Bio (ASX:CMB) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Cambium Bio Net Current Asset Value Related Terms
Cambium Bio Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Cambium Bio's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CMB vs VRTX, REGN, ALNY: Net Current Asset Value Comparison
For the Biotechnology subindustry, Cambium Bio's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambium Bio Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cambium Bio's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Cambium Bio's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of A$0.01 mean?
Cambium Bio (ASX:CMB) has a Net Current Asset Value of A$0.01 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cambium Bio and its competitors. This is 100% below median its historical median of 10.30. Over the past decade, Cambium Bio's Net Current Asset Value has ranged from 3.34 to 47.00. According to the industry distribution chart, Cambium Bio ranks #884 out of 946 companies in the Biotechnology industry, placing it in the top 93.4%.
Is Cambium Bio's Net Current Asset Value too high?
Cambium Bio's current Net Current Asset Value of A$0.01 is 100% below median its 10-year median of 10.30. Over the past 10 years, this metric has ranged from a low of 3.34 to a high of 47.00. Based on the distribution chart, Cambium Bio ranks #884 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Net Current Asset Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cambium Bio ranks #884 out of 946 companies for Net Current Asset Value. This places Cambium Bio in the lower half of its industry. The industry median Net Current Asset Value is 4.86. Historically, Cambium Bio's own Net Current Asset Value has ranged from 3.34 to 47.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.86, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cambium Bio and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambium Bio's current Net Current Asset Value is A$0.01, which is 100% below median its own 10-year median of 10.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Net Current Asset Value of A$0.01. The current Net Current Asset Value is A$0.01, which is 100% below median its 10-year median of 10.30. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Net Current Asset Value is A$0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score
Get the complete analysis for ASX:CMB
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CMB has been successfully added to your 
